Clinical Trials Logo

Nicotine Dependence clinical trials

View clinical trials related to Nicotine Dependence.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06347055 Not yet recruiting - Nicotine Dependence Clinical Trials

NeuroControl of Nicotine Dependence

Start date: July 15, 2024
Phase: N/A
Study type: Interventional

The purpose of the study is to examine the effects of continuous theta burst stimulation (cTBS) on different forms of cognitive control in adults who smoke cigarettes, and to determine if the location where cTBS is delivered may help smokers reduce or quit smoking. Participation in the study will take 3-weeks over 4 visits, with a total time commitment of approximately 12 hours.

NCT ID: NCT06295757 Not yet recruiting - Nicotine Dependence Clinical Trials

Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes.

NCT ID: NCT05962229 Not yet recruiting - Nicotine Dependence Clinical Trials

Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving/withdrawal and enjoyment.

NCT ID: NCT05660798 Not yet recruiting - Clinical trials for Coronary Artery Disease

Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression

SWITCH
Start date: January 2, 2023
Phase: N/A
Study type: Interventional

Objective: To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking. Rationale: Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes. The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.

NCT ID: NCT05587361 Not yet recruiting - Nicotine Dependence Clinical Trials

Beta-Adrenergic Modulation of Drug Cue Reactivity

Start date: June 1, 2024
Phase: Phase 4
Study type: Interventional

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

NCT ID: NCT03450941 Not yet recruiting - Smoking Cessation Clinical Trials

AXS-05 Phase II Trial on Smoking Behavior

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

NCT ID: NCT00429208 Not yet recruiting - Smoking Clinical Trials

Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers

Start date: February 2007
Phase: N/A
Study type: Interventional

This research project addresses the hypothesis that a neurocognitive profile characterized by impairment of response inhibition and sustained attention may be a risk factor for smoking initiation and nicotine dependence among young women. Nicotine has short- term, facilitating effects on attention and response inhibition. Therefore, individuals who are impaired on cognitive functions such as these and initiate cigarette smoking may be more likely to maintain the habit and develop nicotine dependence. The research protocol specifically tests whether administration of nicotine to non-abstinent, regular cigarette smokers improves cognitive function in those domains where the participants had previously been shown to manifest performance deficits